- Home
- GOEV vs BOLT Comparison
GOEV vs BOLT Comparison
Compare GOEV & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOEV
- BOLT
- Stock Information
- Founded
- GOEV 2017
- BOLT 2015
- Country
- GOEV United States
- BOLT United States
- Employees
- GOEV N/A
- BOLT N/A
- Industry
- GOEV
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- GOEV
- BOLT Health Care
- Exchange
- GOEV Nasdaq
- BOLT Nasdaq
- Market Cap
- GOEV 19.6M
- BOLT 22.6M
- IPO Year
- GOEV N/A
- BOLT 2021
- Fundamental
- Price
- GOEV $1.35
- BOLT $0.51
- Analyst Decision
- GOEV Buy
- BOLT Hold
- Analyst Count
- GOEV 6
- BOLT 5
- Target Price
- GOEV $103.10
- BOLT $1.25
- AVG Volume (30 Days)
- GOEV 3.4M
- BOLT 186.2K
- Earning Date
- GOEV 11-13-2024
- BOLT 11-12-2024
- Dividend Yield
- GOEV N/A
- BOLT N/A
- EPS Growth
- GOEV N/A
- BOLT N/A
- EPS
- GOEV N/A
- BOLT N/A
- Revenue
- GOEV $1,864,000.00
- BOLT $9,779,000.00
- Revenue This Year
- GOEV $2,927.65
- BOLT $9.87
- Revenue Next Year
- GOEV $922.67
- BOLT N/A
- P/E Ratio
- GOEV N/A
- BOLT N/A
- Revenue Growth
- GOEV 259.15
- BOLT 35.86
- 52 Week Low
- GOEV $1.04
- BOLT $0.48
- 52 Week High
- GOEV $102.12
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- GOEV 29.03
- BOLT 41.39
- Support Level
- GOEV $1.04
- BOLT $0.50
- Resistance Level
- GOEV $1.79
- BOLT $0.55
- Average True Range (ATR)
- GOEV 0.21
- BOLT 0.04
- MACD
- GOEV 0.35
- BOLT -0.00
- Stochastic Oscillator
- GOEV 41.33
- BOLT 13.04
About GOEV Canoo Inc.
Canoo Inc is a mobility technology company providing with a proprietary modular electric vehicle platform and connected services initially focused on commercial fleet, government and military customers. The Company has developed a breakthrough EV platform that it believes will enable it to rapidly iterate and bring new products, addressing multiple use cases, to market faster than competition and at lower cost.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.